Irebrin is better than dacarbazine in the posterior line of advanced liposarcoma

Share This Post

George D. Demetri and others from the American Dana Fabre / Briegen and Women ‘s Hospital Cancer Center reported that among patients with liposarcoma, the use of iriprine in the back-line treatment had significantly improved survival advantages over dacarbazine. For patients with liposarcoma, the most important thing is to choose iribrin treatment, because the pathological type of the disease has a limited effect on the efficacy. (J Clin Oncol. Online version August 30, 2017)

A previous phase III clinical trial showed that irribrin compared to dacarbazine in the treatment of advanced liposarcoma or leiomyosarcoma can significantly improve overall survival (OS), and the adverse reactions are easy to manage and control. Now the researchers conducted a subgroup analysis of the situation of the iribulin group and the dacarbazine group, with the aim of clarifying the relevant tissue specificity and safety.

Enrollment conditions: patient age ≥18 years; advanced or advanced liposarcoma that cannot be cured by surgery or radiotherapy; ECOG performance status score ≤2; previous chemotherapy regimens ≥2, including anthracycline. Patients were randomly divided into erebrin group (1.4 mg / m2, d1, 8) or dacarbazine group (850 mg / m2, 1000 mg / m2, or 1200 mg / m2, d1) in a 1: 1 ratio. 21 days is a cycle. Study endpoints include OS, progression-free survival (PFS), and safety.

The results showed that the OS in the liposarcoma subgroup was significantly improved. The median OS in the iribulin and dacarbazine groups was 15.6 months and 8.4 months, respectively (HR = 0.51, 95% CI 0.35 ~ 0.75 ; P <001). In the iribulin group, patients with liposarcoma of all histological subtypes and patients in all regions achieved OS improvement. The median PFS of patients in the erebrin group was 2.9 months and 1.7 months relative to the dacarbazine group (HR = 0.52, 95% CI 0.35 ~ 0.78; P = 0.0015). Adverse events were similar between the two groups.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy